TRAW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. TRAW has some bullish longer-term technical structure (stacked moving averages) and genuinely positive pipeline news, but the current setup lacks a fresh momentum trigger (no Intellectia signals; MACD upside is fading) and the price is still below the key pivot (2.375), with short-term pattern stats skewing slightly negative over the next day/week. For an impatient buyer looking to enter immediately, the risk/reward at ~2.08 is not compelling enough versus waiting for either a clean reclaim of 2.375+ or a cleaner pullback toward the 1.89 support area.
Trend/Momentum: Moving averages are bullishly stacked (SMA_5 > SMA_20 > SMA_200), which supports a constructive medium-term trend. However, MACD histogram is positive (0.0417) but ‘positively contracting,’ meaning upside momentum is weakening rather than accelerating. RSI_6 at 42.9 is neutral-to-soft (not oversold), so there isn’t a strong mean-reversion buy signal right now.
Key levels: Current price (2.08 post-market) sits below the pivot at 2.375, implying the stock needs to reclaim that area to confirm near-term strength. Support: S1 at 1.892 (then S2 at 1.594). Resistance: R1 at 2.858 (then R2 at 3.156). Near-term pattern model suggests ~60% chance of mild downside next day/week, with a modest positive bias over the next month.
Phase 2 COVID data: ratutrelvir showed fewer adverse events and no viral rebounds; 600mg daily dose significantly shortened symptom-resolution time.
Influenza pipeline: tivoxavir marboxil new tablet formulation showing >3x effective blood levels; expectation of 28-day protection.
Upcoming event catalyst: planned influenza prophylaxis challenge study in June 2026; positive read-through could support moving toward registration studies.
Street support: H.C. Wainwright initiated with Buy and an $8 price target, highlighting perceived pipeline optionality/upside.
Weak near-term technical trigger: price remains below the 2.375 pivot and MACD upside momentum is fading.
Short-term statistical bias: similar-pattern forecast points to mild downside over the next day/week.
Business stage risk visible in financials: no revenue in the latest quarter and ongoing losses, leaving price action highly dependent on clinical/news flow rather than fundamentals.
Positioning/flow uncertainty: hedge fund and insider trend data is neutral (no strong accumulation signal).
Latest reported quarter: 2025/Q3. Revenue fell to 0 (-100% YoY), consistent with a pre-commercial biotech profile. Net income was -$3.035M (reported as down -64.19% YoY) and EPS was -0.34 (down -96.14% YoY), indicating continued losses and deteriorating per-share results versus the prior year. Gross margin printed 100% but is not meaningful with zero revenue. Overall: fundamentals are not the current driver; clinical milestones are.
Recent trend: one recent initiating coverage call (no multiple revisions shown). On 2025-12-03, H.C. Wainwright initiated at Buy with an $8 price target, citing potential value unlock if early-stage antiviral data continues to replicate. Wall Street pros: clear pipeline-driven upside optionality (COVID + influenza assets) and supportive early clinical messaging. Wall Street cons: single-analyst visibility in the provided data, no valuation support shown, and the investment case hinges on future study outcomes/timelines rather than current revenue traction.
